Advertisement
Singapore markets close in 5 hours
  • Straits Times Index

    3,355.98
    +17.41 (+0.52%)
     
  • Nikkei

    39,693.26
    +62.20 (+0.16%)
     
  • Hang Seng

    17,819.63
    +101.02 (+0.57%)
     
  • FTSE 100

    8,166.76
    +2.64 (+0.03%)
     
  • Bitcoin USD

    63,086.21
    -265.23 (-0.42%)
     
  • CMC Crypto 200

    1,349.29
    +47.22 (+3.63%)
     
  • S&P 500

    5,475.09
    +14.61 (+0.27%)
     
  • Dow

    39,169.52
    +50.66 (+0.13%)
     
  • Nasdaq

    17,879.30
    +146.70 (+0.83%)
     
  • Gold

    2,337.00
    -1.90 (-0.08%)
     
  • Crude Oil

    83.51
    +0.13 (+0.16%)
     
  • 10-Yr Bond

    4.4790
    +0.1360 (+3.13%)
     
  • FTSE Bursa Malaysia

    1,600.58
    +2.38 (+0.15%)
     
  • Jakarta Composite Index

    7,149.02
    +9.40 (+0.13%)
     
  • PSE Index

    6,387.58
    -11.19 (-0.17%)
     

Omega Therapeutics First Quarter 2024 Earnings: Revenues Beat Expectations, EPS In Line

Omega Therapeutics (NASDAQ:OMGA) First Quarter 2024 Results

Key Financial Results

  • Net loss: US$20.1m (loss narrowed by 20% from 1Q 2023).

  • US$0.36 loss per share (improved from US$0.50 loss in 1Q 2023).

earnings-and-revenue-history
earnings-and-revenue-history

All figures shown in the chart above are for the trailing 12 month (TTM) period

Omega Therapeutics Revenues Beat Expectations

Revenue exceeded analyst estimates by 103%. Earnings per share (EPS) was mostly in line with analyst estimates.

Looking ahead, revenue is forecast to grow 64% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Biotechs industry in the US.

Performance of the American Biotechs industry.

ADVERTISEMENT

The company's share price is broadly unchanged from a week ago.

Risk Analysis

What about risks? Every company has them, and we've spotted 5 warning signs for Omega Therapeutics (of which 2 can't be ignored!) you should know about.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.